Scientific program

Wednesday, September 4, 2019

 15:30-15:45 Congress Opening Hall A
Chairpersons Laura Esserman, USA
Bruce Mann, Australia

 15:45-17:30 Plenary Session 1: Neoadjuvant therapy Hall A
Chairpersons Angela DeMichele, USA
Alastair Thompson,
15:45-16:30 Debate: That NACT has little role for ER+ HER2- breast cancer
15:45 Yes: Ingrid A. Mayer, USA
16:00 No: Hope S. Rugo, USA
16:15 Discussion
16:30-16:45 I SPY the future: Using the neoadjuvant model to optimize outcome
Laura Esserman, USA
16:45-17:30 Debate: A path CR allows de-escalation of further therapies
16:45 Yes: Javier Cortes, Spain
17:00 No: Mark D. Pegram, USA
17:15 Discussion
17:30-19:00 Plenary Session 2: Barriers to progress Hall A
Chairpersons Bruce Mann, Australia
Richard de Boer, Australia
17:30-17:50 Why data does often not change opinion
Steven Goodman, USA
17:50-18:20 Debate: That RCTs are the only way to change practice
17:50 Yes: Alistair Ring, UK
18:00 No: Donald Berry, USA
18:10 Discussion
18:20-18:40 How and why the FDA cares about real world evidence
Harpreet Singh, USA
18:40-19:00 Discussion
 19:00 Networking Reception Hall A

Thursday, September 5, 2019

Morning Industry Symposium: 
Supported by Endomag
Breakfast will be served prior to the session
Hall B
Non-CME Track
08:00-09:30 Plenary Session 3: Genetics Hall A
Chairpersons Laura Esserman, USA
Jane Perlmutter, USA
 08:00-08:35 Debate: That most patients with breast cancer should be panel tested
08:00 Yes: Laura Van t’veer, USA
08:10 No: Allison W. Kurian, USA


08:35-09:10 Debate: That all gene carriers with early breast cancer should have a bilateral mastectomy
08:35 Yes: Rita Mukhtar, USA
08:45 No: Ava Kwong, Hong Kong
08:55 Discussion
09:10-09:30 Interplay of lifestyle and genetics in breast cancer
Dean Ornish, USA
09:30-10:30 Parallel Session 4: Endocrine therapy side effects Hall A
Chairpersons Deborah Collyar, USA
Allison W. Kurian,
09:30-10:00 Debate: That topical estrogens are an acceptable treatment in patients with HR+ve early breast cancer
09:30 Yes: Michelle Melisko, USA
09:40 No: Alistair Ring, UK


10:00-10:30 Debate: How to best manage endocrine therapy symptoms: Pharma or Sweat
10:00 Sweat: Michelle Melisko, USA
10:10 Pharma: Sara A. Hurvitz, USA
10:20 Discussion
10:30-11:00 Coffee break and poster viewing  
09:30-10:30 Parallel Session 5: Imaging / Screening
Hall B
Non-CME Track
Chairpersons Bruce Mann, Australia
Nola M. Hylton, USA
09:30 -09:45 MRI screening in women without hereditary risk
Ritse Mann, The Netherlands
09:45-09:55 The implications of a move to MRI screening
Allison Rose, Australia
09:55-10:15 Debate: That women with low risk for breast cancer should only be screened every 3 years
09:55 Yes: Andrea LaCroix, USA
10:05 No:  Heather Greenwood, USA
10:15-10:30 Panel discussion:
Andrea LaCroix, USA
Ritse Mann, The Netherlands
Allison Rose, Australia
Heather Greenwood, USA
10:30-11:00 Coffee break and poster viewing  
11:00-12:35 Parallel Session 6: HER2 positive breast cancer Hall A
Chairpersons Stacy Moulder, USA
Kevin Kalinsky, USA
11:00-11:35 Debate: That all high-risk adjuvant HER-2 patients should receive dual antibody therapy
11:00 Yes: Mark D. Pegram, USA
11:10 No: Antonio Llombart, Spain


11:35-12:10 Debate: That shorter durations of anti HER2 therapy are now warranted in selected patients
11:35 Yes: Sara A. Hurvitz, USA
11:45 No: Javier Cortes, Spain
11:55 Discussion
12:10-12:30 De-escalating therapy in HER2 positive disease
Jo Chien,
12:30-14:00 Lunch break and poster viewing  
11:00-12:30 Parallel Session 7: DCIS Hall B
Non-CME Track
Chairpersons Hiram S. Cody, USA
Donna Pinto, USA
11:00-11:35 Debate: That most DCIS should not be a target for screening
11:00 Yes: Laura Esserman, USA
11:10 No: Bruce Mann, Australia


11:35-12:10 Debate: Most patients with DCIS should not have radiotherapy after Breast Conserving Surgery
11:35 Yes: Alastair Thompson, USA
11:45 No: Thomas A. Buchholz, USA
11:55 Discussion
12:10-12:30 Role of genomic assays in DCIS
Rita Mukhtar, USA
12:30-14:00 Lunch break and poster viewing  
 14:00-15:30 Plenary Session 8: Imaging in systemic disease Hall A
Chairpersons Angela DeMichele, USA
Debra Ikeda, USA
14:00-14:55 Imaging as a biomarker
14:00 Can we predict outcomes using imaging characteristics?
Ritse Mann, The Netherlands
14:15 Lessons from I SPY
Elissa Price, USA
14:30 What is in a sequence: Are all breast MRIs the same?
Nola M. Hylton, USA
14:45 Discussion
14:55-15:30 Debate: That PET CT alone should be the diagnostic tool of choice for metastatic workup for stage 2/3  patients
14:55 Yes: Robert Flavell, USA
15:05 No: Richard de Boer, Australia
15:15 Discussion
15:30-16:00 Coffee break and poster viewing  
16:00-17:30 Parallel Session 9: Issues in locoregional management Hall A
Chairpersons Michael Alvarado, USA
Jiong Wu, China
16:00-16:35 Debate: Despite ACOSOG Z11 and AMAROS, there is still a role for axillary surgery in patients with a positive sentinel node
16:00 Yes: Abigail Caudle, USA
16:10 No: Hiram S. Cody, USA


16:35-17:10 Debate: That regional nodal radiation should be routine for patients with axillary metastasis
16:35 Yes: Thomas A. Buchholz, USA
16:45 No: Catherine Park, USA
16:55 Discussion
17:10-17:30 Management of chronic lymphedema: Are we there yet?
Mark V. Schaverien, USA
16:00-17:30 Parallel Session 10: Free Papers Hall B
Non-CME Track
Chairpersons Javier Cortes, Spain
Richard Schwab, USA
17:30-18:30 Poster Session with drinks Poster area

Friday, September 6, 2019

08:00-09:30 Parallel Session 11: Adjuvant endocrine therapy Hall A
Chairpersons Michelle Melisko, USA
08:00-08:45 Debate: That side effects of dual endocrine therapy outweigh the benefits for most young women
08:00 Yes:Richard De Boer, Australia
08:15 No: Ingrid A. Mayer, USA


08:45-09:30 Debate: That ten years of adjuvant endocrine therapy is overtreatment for most patients
08:45 Yes: Mariana Chavez MacGregor, USA
09:00 No:Richard Schwab, USA
09:15 Discussion
08:00-09:30 Parallel Session 12: Imaging as locoregional staging Hall B
Non-CME Track
Chairpersons Alastair Thompson, USA
Allison Rose, Australia
08:00-08:35 Debate: That axillary ultrasound is an essential part of early breast cancer workup
08:20 Yes: Debra M. Ikeda, USA
08:20 No: Hiram S. Cody, USA
08:20 Discussion
08:35-09:15 Debate: That contrast imaging should be part of the workup of early breast cancer
08:35 Yes: Christiane Kuhl, Germany
08:45 No: Michael Alvarado, USA
08:55 Discussion
09:15-09:30 Intraoperative imaging
Julia Camps-Herrero, Spain
09:30-10:30 Parallel Session 13: Triple negative breast cancer Hall A
Chairpersons Antonio Llombart, Spain
Mariana Chavez MacGregor, USA
09:30-10:10 Debate: That immunotherapy will become standard of care for TN MBC
09:30 Yes: Javier Cortes, Spain
09:45 No: Kevin Kalinsky, USA
10:00 Discussion
10:10-10:30 New strategies in early TNBC
Stacy Moulder, USA
10:30-11:00 Coffee break and poster viewing  
09:30-10:30 Parallel Session 14: Management of impalpable lesions Hall B
Non-CME Track
Chairpersons Judy C. Boughey, USA
Amit Agrawal, UK
09:30-09:40 Why we need to change
Bruce Mann, Australia
09:40-09:50 The case for Magtrace
Michael Alvarado, USA
09:50-10:00 The case for ICG
Ava Kwong, Hong Kong
10:00-10:10 The case for Seeds
Abigail S. Caudle, USA
10:10-10:20 The case for radar localization (Savi Scout)
Tanya Moseley,
10:20-10:30 Discussion
10:30-11:00 Coffee break and poster viewing  
11:00-12:30 Plenary Session 15: Issues in advanced disease Hall A
Chairpersons Ingrid A. Mayer, USA
Sara A. Hurvitz,
11:00-11:35 Debate: After treatment response of denovo metastatic breast cancer, how should the primary lesion be managed?
11:00 Wait and watch: Richard Schwab, USA
11:10 Same as for early stage disease: Judy C. Boughey, USA
11:20 Discussion
11:35-11:55 Oligometastatic disease should be treated with curative intent
Catherine Park, USA
11:55-12:30 Debate: That the ASCO guidelines for palliative care should be internationally applied
11:55 Yes: Michael W. Rabow, USA
12:05 No: Stephen Chia, Canada
12:15 Discussion
12:30-13:45 Lunch break and poster viewing  
12:45-13:45 Industry Lunch Symposium:
HER2-positive early breast cancer:  Determining adjuvant treatment following neoadjuvant therapy
Supported by Genentech
Hall B
Non-CME Track
  HER2-positive early breast cancer:  Determining adjuvant treatment following neoadjuvant  therapy
Francis Arena, USA
13:45-15:15 Parallel Session 16: Reconstruction Hall A
Chairpersons Thomas A. Buchholz, USA
13:45-14:20 Debate: That one surgeon is better than two
13:45 Yes: Amit Agrawal, UK
13:55 No: Mark V. Schaverien, USA
14:05 Discussion
14:20-14:40 Pre-pectoral implants: Does anyone still need a sub muscular implant?
Merisa Piper, USA
14:40-15:15 Debate: That patients requiring postmastectomy radiotherapy should not undergo immediate reconstruction
14:40 Yes: Alastair Thompson, USA
14:50 No: Jiong Wu, China
15:00 Discussion
13:45-15:15 Parallel Session 17: Metastatic Breast Cancer Hall B
Non-CME Track
Chairpersons Mark Pegram, USA
Alistair Ring,
13:45-14:20 Debate: CDK 4/6 inhibitors should be first line therapy for all patients with newly diagnosed HR+ MBC
13:45 Yes: Stephen Chia, Canada
13:55 No: Mariana Chavez MacGregor, USA
14:05 Discussion
14:20-14:40 What is the approach for patients progressing on CDK 4/6 inhibitors?
Angela DeMichele, USA
14:40-15:15 Debate: ctDNA is now the best method to monitor response in patients with metastatic breast cancer
14:40 Yes: Kevin Kalinsky, USA
14:50 No: Antonio Llombart, Spain
15:00 Discussion
15:15-16:15 Plenary Session 18: Vision for breast cancer 2025 Hall A
Chairpersons Bruce Mann, Australia
Alastair Thompson, USA
15:15-15:25 Consumers’ perspective
Jane Perlmutter, USA
15:25-15:35 Early detection
Christiane Kuhl, Germany
15:35-15:45 Pathology
Alexander D. Borowsky, USA
15:45-15:55 Locoregional treatment
Judy C. Boughey, USA
15:55-16:05 Systemic therapy
Angela DeMichele, USA
16:05-16:15 Supportive care
Michael W. Rabow, USA
 16:15-16:30 Congress closing and award presentation Hall A
Chairpersons Bruce Mann, Australia
Alastair Thompson, USA